Goldman Sachs Global Healthcare Conference June 10, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the futur ...

Investor Presentation February 2025 Most robust dataset in wet AMD and DME among all sustained delivery programs in development Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Only sustained release TKI with active program in DME bolstered by highly positive Phase 2 clinical data ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform ...

EyePoint Pharmaceuticals (EYPT) FY Conference June 10, 2025 02:40 PM ET Speaker0 Good afternoon. Thanks for listening. My name is Jay Duker. I'm the president and CEO of EyePoint. I'd like to thank Goldman Sachs for inviting us to present today. And we are a publicly traded company, and I will be giving some forward looking statements. If you'd like our full legal disclaimers, I invite you to go to our website. EyePoint is the leader in sustained release drug delivery for retinal diseases. Our lead asset is ...